145004-89-3

Upstream product

• 89791-76-4 2-amino-3-nitro-4,6-dimethyl-5-bromo-pyridine 
• 5407-87-4 2-Amino-4,6-dimethylpyridine 
• 98-09-9 benzenesulfonyl chloride 
• 138733-52-5 [[2'-[(t-Butylamino)sulfonyl]-1,1'-biphenyl-4-yl]methyl] bromide 
• 133240-06-9 5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine 
• 89856-44-0 2-amino-5-bromo-4,6-dimethylpyridine 
• 50850-16-3 2,3-diamino-4,6-dimethylpyridine 
• 145004-88-2 4'-(2-Ethyl-5,7-dimethyl-imidazo[4,5-b]pyridin-3-ylmethyl)-biphenyl-2-sulfonic acid tert-butylamide 

Downstream Products

• 157263-00-8 MK 996 
• 145004-87-1 5,7-Dimethyl-2-ethyl-3-[(2'-ethoxycarbonylamino sulfonylbiphenyl-4-yl)methyl]-3H-imidazo[4,5-b]pyridine 
• 145004-85-9 5,7-dimethyl-2-ethyl-3-[[2'-(N-cyanoaminosulfonyl)[1,1'-biphenyl]-4-yl]methyl]-3H-imidazo[4,5-b]pyridine 
• 924653-87-2 4-[[[[4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl]amino]carbonyl]-2,2,6,6-tetramethyl-1-piperidinyloxy 

Relevant academic research and scientific papers

Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use

The invention describes compositions and kits comprising at least one nitric oxide enhancing angiotensin II antagonist compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing angiotensin II antagonist compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension (o) treating central nervous system disorders; (p) treating metabolic syndrome; and (q) treating hyperlipidemia. The nitric oxide enhancing angiotensin II antagonist compounds comprise at least one nitric oxide enhancing group linked to the angiotensin II antagonist compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.

3N-Methylbiphenylsulfonylurea and -carbamate substituted imidazo[4,5-b]pyridines. Potent antagonists of the ANG II AT1 receptors

The synthesis and the SAR study of imidazo[4,5-b]pyridine biphenyl sulfonylureas and -carbamates as highly potent AT1-seIective ANG II receptor antagonists are described. Several members of this new class of antagonists efficiently inhibited the ANG II-induced presser response in pithed rats after iv and intraduodenal (id) administration.

L-162,389: A potent orally active angiotensin II receptor antagonist with balanced affinity to both AT1 and AT2 receptor subtypes

Simple modifications made to our potent angiotensin II AT1 selective clinical candidate MK-996 provided a compound with balanced binding affinity to both the AT1 and the AT2 receptor subtype. This compound, L-162,389 is or